CA-19-9 is seen in all except
(A) Breast carcinoma # CA19-9: CA19-9 is a monoclonal antibody generated against a colon carcinoma cell line to detect a monosialoganglioside found in patients with gastrointestinal adenocarcinoma.> It is found to be elevated in 21 to 42 percent of cases of gastric cancer, 20 to 40 percent of colon cancer, and 71 to 93 percent of pancreatic cancer, and has been proposed to differentiate benign from malignant pancreatic disease, but this capability remains to be established.> CA19-9 (carbohydrate antigen 19-9 or sialylated Lewis (a) antigen) is a blood test from the tumor marker category.> It was discovered in patients with colon cancer and pancreatic cancer in 1981. Increased levels of CA19-9 are also found in non- malignant conditions, such as Mirizzi's syndrome and diseases of the bile ducts and liver.> The main use of CA19-9 is to see whether a pancreatic tumor is secreting it; if that is the case, then the levels should fall when the tumor is treated, and they may rise again if the disease recurs.> In patients who lack the Lewis antigen (a blood type protein on red blood cells), which is about 5% of the population, CA19-9 is not elevated in pancreatic cancer even with large tumors because they have a deficiency of a fucosyltransferase enzyme that is needed to produce CA19-9 as well as the Lewis antigen.
Breast carcinoma
Ovarian carcinoma
Colonic carcinoma
Pancreatic carcinoma
Misc.